Hainan Honz Pharmaceutical Co
Honz Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and sales of pediatric medicines in China. The company offers medicines for children and adults in the areas of anti-anaphylaxis, antidiarrheal and digestive, relieving cough, anti-flu, antipyretic, anti-infection, anti-fungal, antipyretic-analgesic, and endocrine; and medical, disposable, and protective face ma… Read more
Hainan Honz Pharmaceutical Co (300086) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.009x
Based on the latest financial reports, Hainan Honz Pharmaceutical Co (300086) has a cash flow conversion efficiency ratio of -0.009x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-9.17 Million) by net assets (CN¥1.07 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Hainan Honz Pharmaceutical Co - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Hainan Honz Pharmaceutical Co's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Hainan Honz Pharmaceutical Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hainan Honz Pharmaceutical Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CAP S.A
SN:CAP
|
0.038x |
|
PolyNovo Limited
PINK:CALZF
|
0.190x |
|
Hana Microelectronics Public Company Limited
PINK:HMICF
|
0.030x |
|
Myriad Genetics Inc
NASDAQ:MYGN
|
0.029x |
|
Shenzhen Minkave Technology Co Ltd
SHE:300506
|
1.152x |
|
Petrovietnam Gas JSC
VN:GAS
|
0.012x |
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
-0.217x |
|
Apotea
ST:APOTEA
|
N/A |
Annual Cash Flow Conversion Efficiency for Hainan Honz Pharmaceutical Co (2007–2024)
The table below shows the annual cash flow conversion efficiency of Hainan Honz Pharmaceutical Co from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | CN¥71.46 Million | 0.061x | +19.53% |
| 2023-12-31 | CN¥1.38 Billion | CN¥70.69 Million | 0.051x | +137.15% |
| 2022-12-31 | CN¥1.36 Billion | CN¥29.32 Million | 0.022x | +196.65% |
| 2021-12-31 | CN¥1.55 Billion | CN¥11.33 Million | 0.007x | +169.76% |
| 2020-12-31 | CN¥1.60 Billion | CN¥-16.74 Million | -0.010x | -137.16% |
| 2019-12-31 | CN¥1.60 Billion | CN¥45.06 Million | 0.028x | -70.50% |
| 2018-12-31 | CN¥1.65 Billion | CN¥157.66 Million | 0.095x | +907.72% |
| 2017-12-31 | CN¥1.92 Billion | CN¥18.17 Million | 0.009x | -80.51% |
| 2016-12-31 | CN¥1.87 Billion | CN¥90.88 Million | 0.049x | +14.15% |
| 2015-12-31 | CN¥1.84 Billion | CN¥78.30 Million | 0.043x | +3.78% |
| 2014-12-31 | CN¥1.80 Billion | CN¥73.93 Million | 0.041x | -6.05% |
| 2013-12-31 | CN¥1.81 Billion | CN¥78.93 Million | 0.044x | -25.37% |
| 2012-12-31 | CN¥1.87 Billion | CN¥109.46 Million | 0.058x | +207.30% |
| 2011-12-31 | CN¥1.85 Billion | CN¥-100.94 Million | -0.054x | -224.62% |
| 2010-12-31 | CN¥1.83 Billion | CN¥79.89 Million | 0.044x | -88.77% |
| 2009-12-31 | CN¥240.49 Million | CN¥93.58 Million | 0.389x | -6.52% |
| 2008-12-31 | CN¥150.41 Million | CN¥62.61 Million | 0.416x | +57.69% |
| 2007-12-31 | CN¥115.89 Million | CN¥30.59 Million | 0.264x | -- |